US/UK/Canada

Share

Contacts

  • STENOCARE A/S
    Nyholmsvej 4 8930 Randers NØ Danmark
    +45 31 77 00 60
    http://www.stenocare.com

    • Quotes

    “We are closely monitoring the weekly sales across our distribution channels to have products ready for patients at all the Danish pharmacies. We have heard concerns from politicians, that there might be challenges securing supply for Denmark. With our ongoing market monitoring and import of products – we will be able to meet the entire demand from all Danish patients”.
    Rolf Steno, CCO
    Pick a time period -
    Tags ( Active)

    STENOCARE Change in the Board of Directors

    STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER:  STENOThis information is information that STENOCARE A/S is obliged to publish in accordance with the EU Market Abuse Regulation. The information was provided by the contact person below for publication on November 01, 2024. STENOCARE A/S (“Stenocare” or the “Company”) is changing the Board of Directors. Board member Søren Kjær will leave the board. The Company will nominate Rolf Steno to join the Board at the next general meeting. The Company has accepted the resignation from Board member Søren Kjær and would like to

    STENOCARE updates guidance for 2024

    STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER:  STENO This information is information that STENOCARE A/S is obliged to publish in accordance with the EU Market Abuse Regulation. The information was provided by the contact person below for publication on October 14, 2024. STENOCARE A/S (“Stenocare” or the “Company”) is updating its guidance from August 20 2024, based on actual market performance in Q3 2024 which has impacted the Company’s 2024 guidance. The guidance of gross sales of between 6-8 mDKK is now expected to be 4.5 mDKK for 2024. The Company is exploring

    Interim Report Second Quarter 2024

    STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER: STENO STENOCARE A/S (“STENOCARE”) today announces its results for the period 01.01.2024 – 30.06.2024. The report, which has not been reviewed by the Company’s auditors, is attached to this release and is also available on https://stenocare.com/investor-relations/Thomas Skovlund Schnegelsberg, CEO of STENOCARE, comments:”Stenocare sales are lower than expected even though we have successfully managed to further improve financial health of the Company and launch new products in several markets, thereby delivering on our

    STENOCARE updates guidance for 2024

    STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER:  STENO This information is information that STENOCARE A/S is obliged to publish in accordance with the EU Market Abuse Regulation. The information was provided by the contact person below for publication on August 20, 2024. STENOCARE A/S (“Stenocare” or the “Company”) is updating the guidance from November 06, 2023 based on actual market performance from Q1 and Q2 2024 and the forecast for Q3 and Q4 2024. The guidance of gross sales of 12-18 mDKK is now expected to be 6-8 mDKK for 2024, which is a growth of +7% compared

    New innovative Stenocare Astrum 10-10 oil product is ready for sale in Germany

    STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER:  STENO STENOCARE A/S (Stenocare) and ADREXpharma are now ready to deliver a new and innovative medical cannabis oil product for German patients, that has the potential to revolutionize the market.Stenocare and ADREXpharma have received approval to sell a new and innovative medical cannabis oil product in Germany, set to be available for patients in the fourth quarter of 2024.   The new product is a THC-CBD 10-10 oil in a 30 ml bottle which has the potential to address a large target group of patients in the German

    STENOCARE A/S: Directed issue, refinancing of debt from a major shareholder and new dates

    STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER: STENOThis information is information that STENOCARE A/S is obliged to publish in accordance with the EU Market Abuse Regulation. The information was provided by the contact person below for publication on June 28, 2024. The existing debt On 12 January 2024, STENOCARE A/S (“Stenocare” or the “Company”) announced that it had refinanced its total debt of approximately 8.2 mDKK. Through partial repayment, renegotiation, and extension, the debt was reduced to approximately 5.4 mDKK. As of 30 June 2024, the debt stands at

    TO2 Warrant Exercise subscribed to 88.3%

    STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER:  STENOThis information is information that STENOCARE A/S is obliged to publish in accordance with the EU Market Abuse Regulation. The information was provided by the contact person below for publication on 25 June 2024. Outcome of TO2 Warrant Exercise STENOCARE A/S (“Stenocare” or the “Company”) announces the outcome of the exercise of its TO2 warrant (“Warrants”) exercise. The Warrants were issued in connection with the executed unit rights issue in May/June 2023 and conversion of 5 mDKK debt in June 2023. Total number

    STENOCARE: Notice for deadline of subscribing at the discounted price of DKK 3.16 per share

    STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER: STENO The Stenocare TO2 Warrant subscription will end at the close of business on June 21. To benefit from the discounted share price of DKK 3.16 each, owners of TO2 Warrants must exercise their warrants before the deadline.Stenocare is currently offering a time-limited share issue for owners of TO2 Warrants. Owners can subscribe (ie. purchase) new Stenocare shares at a discounted price of DKK 3.16 each. The deadline for subscription at the discounted price is June 21, 2024, at 17:00 Central European Summer Time. TO2

    STENOCARE A/S: Notice for deadline of trading TO2 Warrants

    STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER: STENO Stenocare TO2 Warrant trading will end close of business June 19. To benefit from the discounted share price of DKK 3.16 each, subscribers need to own TO2 Warrants (ticker: STENO TO2).Stenocare is currently offering a time-limited share issue for owners of TO2 Warrants. These warrants can be purchased and/or sold until the deadline of June 19, 2024, at 17:00 Central European Summer Time. The TO2 Warrants can be used to subscribe to (purchase) the new Stenocare shares at a discounted price of DKK 3.16 each during

    STENOCARE is expanding into Canada

    STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER: STENOSTENOCARE A/S (“Stenocare”), one of Europe’s Leading Medical Cannabis pharma companies is expanding into Canada together with North American Industry experts to lead its expansion efforts. Stenocare is working to expand into Canada. With a population of 37 mill, Canada is a global leader in the legalization of cannabis for medical purposes, and other countries are seeing Canada as a reference for their own path toward the legalization of cannabis. Stenocare is now bringing its flagship suite of products to the

    STENOCARE A/S: Publication of investment brochure

    STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER: STENONOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE. STENOCARE A/S (“Stenocare” or the “Company”) announced the exercise price of 3.16 DKK per share in relation to the TO2 warrant exercise. The exercise

    STENOCARE is shortlisted for European Cannabis Company of the Year

    STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER:  STENO STENOCARE A/S (“Stenocare”) is honored to be recognized as one of the leading European Cannabis Companies in the industry annual award.Stenocare has been an active participant in the European medical cannabis industry since it was founded in 2017. The company has entered six different countries with prescription-based medical cannabis products and has been an active participant in developing these markets. Now, Stenocare has been nominated and shortlisted in the annual industry awards as one of the best European

    STENOCARE A/S: Announcement of Exercise Price of Warrants of Series TO2

    STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER:  STENOThis information is information that STENOCARE A/S is obliged to publish in accordance with the EU Market Abuse Regulation. The information was provided by the contact person below for publication on June 07, 2024. NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION

    An Update on STENOCARE's Strong Product Pipeline

    STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER:  STENO STENOCARE A/S (“Stenocare”) is providing an update on the progress of its robust product pipeline, spanning four stages from concept to commercialization. A significant milestone has recently been achieved with the innovative ASTRUM OIL product.Since 2018, Stenocare has been the leading provider of medical cannabis oil products for the Danish Pilot Programme and has expanded into five other markets with approved products. Stenocare operates today in Denmark, Sweden, Norway, Germany, the United Kingdom, and Australia.

    STENOCARE launch next generation medical cannabis oil product in Australia – six months ahead of schedule

    STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER: STENO STENOCARE A/S (“Stenocare”) today announces their new innovative product-line is ready for the market – six months ahead of expectation. The new Astrum brand is an innovative cannabis oil product featuring a patented oil technology that enhances the bioavailability of its active ingredients. This breakthrough allows for higher uptake in the blood, and reduced dosage requirements. The first Astrum product will be launched for patients in Australia during Summer 2024.Ahead of plan: Stenocare has since 2019 been

    STENOCARE is sharing early information about the upcoming share issue “TO2 Warrant” transaction in June 2024

    STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER:  STENOSTENOCARE A/S (“Stenocare”) announced a year ago (May 2023) that the company would raise capital through three different share issue transactions. The last of these transactions is the upcoming “TO2 Warrant” transaction, starting on June 10, 2024. Important: Only owners of TO2 Warrants will be able to subscribe (buy) new Stenocare shares at a 30% discount during the transaction window from June 10-21. Stenocare like to highlight the following points about the TO2 Warrant transaction: · Owning TO2 Warrants is a

    COMMUNIQUE FROM THE ANNUAL GENERAL MEETING OF STENOCARE

    STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER:  STENOAnnual general meeting On 14 May 2024 annual general meeting of shareholders of STENOCARE A/S, CVR no. 39024705, was held at Lund Elmer Sandager Law Firm, Kalvebod Brygge 39-41, DK-1560 København V with the following agenda: Agenda: 1. Appointment of a chairman of the meeting 2. Report of the chairman of the board of directors 3. Presentation of the annual report together with a resolution for its adoption 4. Resolution to appropriate the profit or cover the loss 5. Election of members of the board of

    Interim Report First Quarter 2024

    STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER: STENOSTENOCARE A/S (“STENOCARE”) today announces its results for the period 01.01.2024 – 31.03.2024. The report, which has not been reviewed by the Company’s auditors, is attached to this release and is also available on https://stenocare.com/investor-relations/ Thomas Skovlund Schnegelsberg, CEO of STENOCARE, comments: ”Stenocare has successfully managed to launch new approved products and sales has seen positive growth during Q1 2024" [](KDKK) 01.01.2024 01.01.2023 01.01.2023 01.12.2022

    Notice to Annual General Meeting in STENOCARE A/S

    STENOCARE A/SNASDAQ FIRST NORHT GROWTH MARKET, DENMARKTICKER: STENOThe board of directors hereby convenes the shareholders of STENOCARE to the Annual General Meeting, which will be held: STENOCARE A/S 14 May 2024 at 3:00 PM (CEST) (the doors open at 2:30 PM)                                   at Lund Elmer Sandager Law Firm Kalvebod Brygge 39-41 DK-1560 København V With the following agenda: 1. Appointment of a chairman of the meeting 2. Report of the chairman of the board of directors 3. Presentation of the annual report together with a resolution for its

    From today, the new STENOCARE THC/CBD medical cannabis oil product is available for sale in Denmark

    STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER:  STENO On February 26, 2024, STENOCARE A/S (“Stenocare”) announced, that it had received approval to supply a new THC/CBD medical cannabis oil product under the Danish Pilot Programme. Starting today the new product is available for sales to patients, and Stenocare is the only supplier of THC/CBD oil products under the Pilot. Out of the many suppliers seeking approval to sell their products, Stenocare has been in a clear leadership position from the start of the Pilot in 2018 and is the only supplier of three different

    STENOCARE A/S publishes Annual Report 2023

    STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER: STENO The Board of Directors and the Chief Executive Officer of STENOCARE A/S (“STENOCARE”) hereby publishes the annual report of the fiscal year 2023. The annual report including the auditor’s report is available as an attached file and on the website of STENOCARE and Nasdaq First North .Thomas Skovlund Schnegelsberg, CEO of STENOCARE, comments: ”2023 WAS ABOUT SECURING PRODUCT APPROVALS, SALES GROWTH AND

    New Stenocare product ready for sale in Australia

    STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER:  STENO STENOCARE A/S (Stenocare) and its partners are now ready to deliver a new medical cannabis oil product for Australian patients.Stenocare announced in November 2023 that the company and its partners had received approval for a new medical cannabis oil product in Australia, set to be available for patients in the first quarter of 2024. This week (March 12), the new product is officially released and made ready for sale to Australian patients. The new product is a "Balanced 25-25 oil" in a 30 ml bottle which has the

    Major milestone reached: STENOCARE receives approval to sell a new medical cannabis oil product in Denmark

    STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER:  STENO This information is information that STENOCARE A/S is obliged to publish in accordance with the EU Market Abuse Regulation. The information was provided by the contact person below for publication on February 26, 2024 STENOCARE A/S (“Stenocare”) hereby announces that it has received approval from The Danish Medicines Agency to sell a new THC/CBD medical cannabis oil product to Danish patients. With this, Stenocare has regained the position as the exclusive (only) provider of all three essential oil products under

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media